NewsRamp Psychedelics Podcast

NewsRamp Psychedelics Podcast

Explore the emerging world of psychedelics with the 'NewsRamp Psychedelics Podcast.' This podcast delivers the latest news and insights from NewsRamp.com, focusing on research developments, therapeutic applications, and regulatory changes in the psychedelics field. Stay informed on the groundbreaking advancements in this evolving industry.

Episodes

Helus Pharma Appoints Jill Conwell as Chief People Officer

March 12, 2026 • 1 min
Helus Pharma appoints Jill Conwell, a seasoned leader in the life sciences industry, to drive talent strategy and organizational development. Visit the company's newsroom for details.
Mark as Played

Transforming Mental Health with IV Ketamine Therapy

March 3, 2026 • 1 min
Dr. Austin Harris of NeuroRelief Ketamine & Infusion Therapy in Los Angeles provides personalized ketamine treatment plans with high success rates, offering continuous support to patients.
Mark as Played

Pharma Companies Making Strategic Moves: NRx Pharmaceuticals Debt-Free & Cybin Inc. Transfers to Nasdaq

December 18, 2025 • 2 mins
NRx Pharmaceuticals has eliminated its balance sheet debt through an equity conversion, positioning the company to be debt-free by the end of 2025. Meanwhile, Cybin Inc. is transferring its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market, with common shares set to trade under the ticker symbol 'HELP' starting Jan. 5, 2026. Both companies are focused on advancing innovative mental health treatments and exp...
Mark as Played

Cybin Inc. Reports Strong Growth and Progress in Mental Healthcare Innovations

November 13, 2025 • 2 mins
Cybin Inc., a leading neuropsychiatry company, recently announced its successful second-quarter results and highlighted key advancements in its clinical trials and global regulatory approvals. With a focus on revolutionizing mental healthcare, Cybin is actively developing new treatment options for conditions like major depressive disorder and generalized anxiety disorder. George Tziras, the chief business officer, will be presentin...
Mark as Played

Revolutionizing Mental Healthcare: Cybin Inc. Conference Call Overview

November 6, 2025 • 1 min
Cybin Inc., a leading neuropsychiatry company, will be hosting a conference call to discuss Q2 results and provide updates on their innovative treatment options for mental health disorders. Founded in 2019, Cybin is focused on developing solutions for major depressive disorder and generalized anxiety disorder, operating in multiple countries including Canada, the U.S., the U.K., and Ireland. For more details, visit Cybin's newsroom...
Mark as Played

Revolutionizing Mental Healthcare: Cybin Inc.'s Innovative Drug Development

November 5, 2025 • 2 mins
Cybin Inc., a Phase 3 clinical stage neuropsychiatry company, is set to have their Chief Business Officer speak at the Guggenheim 2nd Annual Healthcare Innovation Conference. The company is dedicated to transforming mental healthcare through the development of novel drugs like CYB003 and CYB004 for major depressive disorder and generalized anxiety disorder, respectively, with the goal of providing effective and lasting treatment op...
Mark as Played

Global Psychedelic Week 2025: Uniting the World in Psychedelic Conversation

November 3, 2025 • 3 mins
Global Psychedelic Week 2025 is the first-ever distributed psychedelic conference, gathering 5,000 participants from 100 countries through a hybrid online and in-person model. With over 100 speakers like Rick Doblin and Robin Carhart-Harris, the event aims to spark global conversations on psychedelic science, therapy, and culture. By hosting in-person gatherings worldwide, GPW fosters a truly global movement from the ground up, pro...
Mark as Played

Revolutionizing Mental Healthcare: Cybin Inc. to Present at 2025 Milken Institute Future of Health Summit

November 3, 2025 • 1 min
Cybin Inc., a Phase 3 clinical-stage neuropsychiatry company, will have its Chief Medical Officer, Amir Inamdar, speak at the upcoming 2025 Milken Institute Future of Health Summit in Washington, D.C. The company is dedicated to transforming mental healthcare through innovative treatment options like CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder. Operating in multiple countries since its founding ...
Mark as Played

Cybin Inc. Announces $175M Direct Offering for Mental Health Treatment Development

October 29, 2025 • 2 mins
Cybin Inc. has revealed a registered direct offering of common shares and warrants, raising over $175 million in gross proceeds. The offering includes renowned investors and aims to support the development of innovative treatment options for mental health conditions like major depressive disorder and generalized anxiety disorder.
Mark as Played

Celebrate the Transformative Power of Psychedelics at Global Psychedelic Week 2025

October 27, 2025 • 2 mins
Global Psychedelic Week 2025 offers a diverse program with seven themed days, over 100 events, and 140 speakers from around the world. From scientific discovery to indigenous wisdom, the event explores the evolving landscape of psychedelic research. Visionary voices like Robin Carhart-Harris and Rick Doblin will discuss the fusion of ancient wisdom and modern science. With 5,000 participants from 100 countries, the event aims to un...
Mark as Played

Global Psychedelic Week 2025: A Worldwide Exploration of Psychedelic Therapies and Perspectives

October 20, 2025 • 2 mins
Global Psychedelic Week 2025 will feature 130 global speakers and 100 in-person events worldwide, including discussions on psychedelic therapies in crisis zones, evidence-based approaches in psychedelic enterprises, indigenous perspectives, women in psychedelics, and the role of psychedelics in addressing climate change. The conference aims to decentralize the conversation and prioritize inclusivity and community, with early bird r...
Mark as Played

Advancements in Preservative-Free Ketamine Therapies by NRx Pharmaceuticals

October 17, 2025 • 1 min
NRx Pharmaceuticals is making significant progress in developing preservative-free ketamine-based therapies through two different pathways, including KETAFREE and NRX-100. With FDA approval to remove benzethonium chloride for KETAFREE and Fast Track Designation for NRX-100, the company is demonstrating a commitment to innovative treatments for mental health disorders. CEO Dr. Jonathan Javitt recently highlighted these advancements ...
Mark as Played

FDA Approval Secured for Preservative-Free Ketamine: NRx Pharmaceuticals Expands Market Opportunity

October 7, 2025 • 1 min
NRx Pharmaceuticals Inc. has received FDA approval for a Suitability Petition, allowing them to re-file for their preservative-free ketamine product. This aligns with NRx's focus on developing treatments for suicidal depression and PTSD, while tapping into the growing demand for safer pharmaceutical options in the U.S. market.
Mark as Played

Uniting the World: Global Psychedelic Week 2025

October 2, 2025 • 1 min
Global Psychedelic Week 2025, the first distributed psychedelic conference, will bring together 5,000 people from 100 countries with 100+ speakers like Rick Doblin and Robin Carhart-Harris. With events in nearly 60 cities and partnerships with 70+ organizations, GPW aims to promote global dialogue and action on psychedelics. Early bird registration is now open at www.globalpsychedelicweek.com.
Mark as Played

Advancements and Milestones in Neuropsychiatry Drug Development by Cybin Inc.

September 24, 2025 • 2 mins
Cybin Inc. provided updates on its drug discovery platforms, highlighting key milestones such as upcoming Phase 2 and Phase 3 program data releases for anxiety and depression disorders, along with a strategic manufacturing partnership. The Company's intellectual property portfolio is secured until 2041, with promising response rates and FDA Breakthrough Therapy Designation for its CYB003 program.
Mark as Played

Fireside Chat at TD Cowen's Summit with Cybin Inc. Executives

September 12, 2025 • 2 mins
Cybin Inc.'s Chief Medical Officer and Chief Business Officer will be participating in a fireside chat at an upcoming summit to discuss the company's focus on developing innovative treatment options for mental health conditions, including their ongoing Phase 3 and Phase 2 studies for major depressive disorder and generalized anxiety disorder, respectively. Established in 2019, Cybin is a clinical-stage neuropsychiatry company with ...
Mark as Played

Advancements in Mental Health Treatments: NRx Pharmaceuticals and Cybin Inc. Acquisitions and Developments

September 9, 2025 • 2 mins
NRx Pharmaceuticals' subsidiary HOPE Therapeutics Inc. has acquired Dura Medical, a provider of interventional psychiatry services in Florida, expanding its network. Meanwhile, Cybin Inc. has completed enrollment in its Phase 2 study of CYB004 for Generalized Anxiety Disorder, with topline data expected in Q1 2026, aiming to address the needs of millions of Americans living with GAD.
Mark as Played

Cybin Inc. Chief Business Officer to Speak at H.C. Wainwright Conference

September 4, 2025 • 1 min
Cybin Inc., a neuropsychiatry company, will have their Chief Business Officer participating in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference to discuss their focus on developing new treatment options for mental health conditions, including CYB003 in Phase 3 studies for major depressive disorder and CYB004 in a Phase 2 study for generalized anxiety disorder. Established in 2019, Cybin is actively op...
Mark as Played

Fireside Chat with Cybin Inc.'s CMO at Cantor Global Healthcare Conference

September 3, 2025 • 1 min
Cybin Inc.'s Chief Medical Officer, Amir Inamdar, will be participating in a fireside chat at the Cantor Global Healthcare Conference on September 5, 2025, discussing the company's focus on developing new treatment options for mental health conditions such as major depressive disorder and generalized anxiety disorder. The session will be webcast live and available for replay on Cybin's investor relations website. Founded in 2019, C...
Mark as Played

Leadership Changes and Treatment Advancements in Mental Health Companies

September 2, 2025 • 2 mins
Cybin Inc. appoints Eric So as Interim CEO following Doug Drysdale's resignation, focusing on advancing clinical pipeline for mental health conditions. Meanwhile, NRx Pharmaceuticals Inc. secures FDA Fast Track designation for IV ketamine formulation NRX-100 in treating suicidal depression, expanding its potential patient pool.
Mark as Played

Popular Podcasts

    Stuff You Should Know

    Stuff You Should Know

    If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.

    Dateline NBC

    Dateline NBC

    Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com

    Betrayal Season 5

    Betrayal Season 5

    Saskia Inwood woke up one morning, knowing her life would never be the same. The night before, she learned the unimaginable – that the husband she knew in the light of day was a different person after dark. This season unpacks Saskia’s discovery of her husband’s secret life and her fight to bring him to justice. Along the way, we expose a crime that is just coming to light. This is also a story about the myth of the “perfect victim:” who gets believed, who gets doubted, and why. We follow Saskia as she works to reclaim her body, her voice, and her life. If you would like to reach out to the Betrayal Team, email us at betrayalpod@gmail.com. Follow us on Instagram @betrayalpod and @glasspodcasts. Please join our Substack for additional exclusive content, curated book recommendations, and community discussions. Sign up FREE by clicking this link Beyond Betrayal Substack. Join our community dedicated to truth, resilience, and healing. Your voice matters! Be a part of our Betrayal journey on Substack.

    The Dan Bongino Show

    The Dan Bongino Show

    The Dan Bongino Show delivers no-nonsense analysis of the day’s most important political and cultural stories. Hosted by the former Deputy Director of the FBI, former Secret Service agent, NYPD officer, and bestselling author Dan Bongino, the show cuts through media spin with facts, accountability, and unapologetic conviction. Whether it’s exposing government overreach, defending constitutional freedoms, or connecting the dots the mainstream media ignores, The Dan Bongino Show provides in-depth analysis of the issues shaping America today. Each episode features sharp commentary, deep dives into breaking news, and behind-the-scenes insight you won’t hear anywhere else. Apple: https://podcasts.apple.com/us/podcast/the-dan-bongino-show/id965293227?mt=2 Spotify: https://open.spotify.com/show/4sftHO603JaFqpuQBEZReL?si=PBlx46DyS5KxCuCXMOrQvw Rumble: https://rumble.com/c/bongino?e9s=src_v1_sa%2Csrc_v4_sa_o

    The Breakfast Club

    The Breakfast Club

    The World's Most Dangerous Morning Show, The Breakfast Club, With DJ Envy, Jess Hilarious, And Charlamagne Tha God!

Advertise With Us
Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

Explore

iHeart

Live Radio

Podcasts

Artist Radio

Exclusives

News

Features

Events

Contests

Photos

Information

About

Advertise

Blog

Brand Guidelines

Contest Guidelines

Subscription Offers

Jobs

Get the App

Automotive

Home

Wearables

© 2026 iHeartMedia, Inc.